|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sasako M, Sakuramoto S, Katai H, Kinoshita
T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and
Ohashi Y: Five-year outcomes of a randomized phase III trial
comparing adjuvant chemotherapy with S-1 versus surgery alone in
stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Songun I, Keizer HJ, Hermans J,
Klementschitsch P, de Vries JE, Wils JA, van der Bijl J, van
Krieken JH and van de Velde CJ: Chemotherapy for operable gastric
cancer: Results of the Dutch randomised FAMTX trial. The Dutch
gastric cancer group (DGCG). Eur J Cancer. 35:558–562. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. N Engl J Med.
355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ychou M, Boige V, Pignon JP, Conroy T,
Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM,
Saint-Aubert B, et al: Perioperative chemotherapy compared with
surgery alone for resectable gastroesophageal adenocarcinoma: An
FNCLCC and FFCD multicenter phase III trial. J Clin Oncol.
29:1715–1721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hofheinz RD, Merx K, Haag GM, Springfeld
C, Ettrich T, Borchert K, Kretzschmar A, Teschendorf C, Siegler G,
Ebert MP, et al: FLOT versus FLOT/trastuzumab/pertuzumab
perioperative therapy of human epidermal growth factor receptor
2-positive resectable esophagogastric adenocarcinoma: A randomized
phase II Trial of the AIO EGA study group. J Clin Oncol.
JCO2200380. 2022.(epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peng L, Yang W, Zhang Z, Liu H and Hua Y:
Clinical features and prognosis analysis of 21 gastric cancer
patients with pathological complete response after neoadjuvant
chemotherapy. Zhonghua Wei Chang Wai Ke Za Zhi. 20:1168–1173.
2017.(In Chinese). PubMed/NCBI
|
|
8
|
Cho H, Nakamura J, Asaumi Y, Yabusaki H,
Sakon M, Takasu N, Kobayashi T, Aoki T, Shiraishi O, Kishimoto H,
et al: Long-term survival outcomes of advanced gastric cancer
patients who achieved a pathological complete response with
neoadjuvant chemotherapy: A systematic review of the literature.
Ann Surg Oncol. 22:787–792. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Y, Peng Z and Chen L: Survival
analysis of gastric cancer cases with pathological complete
response received neoadjuvant chemotherapy. Zhonghua Yi Xue Za Zhi.
96:1582–1584. 2016.(In Chinese). PubMed/NCBI
|
|
10
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY
and Shen KH: Peritoneal carcinomatosis and lymph node metastasis
are prognostic indicators in patients with Borrmann type IV gastric
carcinoma. Hepatogastroenterology. 49:874–877. 2002.PubMed/NCBI
|
|
12
|
Japanese Gastric Cancer Association, .
Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric
Cancer. 20:1–19. 2017. View Article : Google Scholar
|
|
13
|
Grenader T, Waddell T, Peckitt C, Oates J,
Starling N, Cunningham D and Bridgewater J: Prognostic value of
neutrophil-to-lymphocyte ratio in advanced oesophago-gastric
cancer: Exploratory analysis of the REAL-2 trial. Ann Oncol.
27:687–692. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bruixola G, Caballero J, Papaccio F,
Petrillo A, Iranzo A, Civera M, Moriana M, Bosch N, Maroñas M,
González I, et al: Prognostic nutritional index as an independent
prognostic factor in locoregionally advanced squamous cell head and
neck cancer. ESMO Open. 3:e0004252018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Okugawa Y, Toiyama Y, Yamamoto A,
Shigemori T, Ide S, Kitajima T, Fujikawa H, Yasuda H, Hiro J,
Yoshiyama S, et al: Lymphocyte-C-reactive protein ratio as
promising new marker for predicting surgical and oncological
outcomes in colorectal cancer. Ann Surg. 272:342–351. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kwee RM and Kwee TC: Imaging in assessing
lymph node status in gastric cancer. Gastric Cancer. 12:6–22. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ajani JA, Bentrem DJ, Besh S, D'Amico TA,
Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, et
al: Gastric cancer, version 2.2013: Featured updates to the NCCN
guidelines. J Natl Compr Canc Netw. 11:531–546. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okines A, Verheij M, Allum W, Cunningham D
and Cervantes A; ESMO Guidelines Working Group, : Gastric cancer:
ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 21 (Suppl 5):v50–v54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Waddell T, Verheij M, Allum W, Cunningham
D, Cervantes A and Arnold D; European Society for Medical Oncology
(ESMO); European Society of Surgical Oncology (ESSO); European
Society of Radiotherapy and Oncology (ESTRO), : Gastric cancer:
ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 24 (Suppl 6):vi57–vi63. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schuhmacher C, Gretschel S, Lordick F,
Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan
B, Welch J, et al: Neoadjuvant chemotherapy compared with surgery
alone for locally advanced cancer of the stomach and cardia:
European organisation for research and treatment of cancer
randomized trial 40954. J Clin Oncol. 28:5210–5218. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park SR, Lee JS, Kim CG, Kim HK, Kook MC,
Kim YW, Ryu KW, Lee JH, Bae JM and Choi IJ: Endoscopic ultrasound
and computed tomography in restaging and predicting prognosis after
neoadjuvant chemotherapy in patients with locally advanced gastric
cancer. Cancer. 112:2368–2376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Redondo-Cerezo E, Martínez-Cara JG,
Jiménez-Rosales R, Valverde-López F, Caballero-Mateos A,
Jérvez-Puente P, Ariza-Fernández JL, Úbeda-Muñoz M, López-de-Hierro
M and de Teresa J: Endoscopic ultrasound in gastric cancer staging
before and after neoadjuvant chemotherapy. A comparison with PET-CT
in a clinical series. United European Gastroenterol J. 5:641–647.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
organization for research and treatment of cancer, national cancer
institute of the United States, national cancer institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Smyth EC, Fassan M, Cunningham D, Allum
WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M,
et al: Effect of pathologic tumor response and nodal status on
survival in the medical research council adjuvant gastric
infusional chemotherapy trial. J Clin Oncol. 34:2721–2727. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tomasello G, Petrelli F, Ghidini M,
Pezzica E, Passalacqua R, Steccanella F, Turati L, Sgroi G and
Barni S: Tumor regression grade and survival after neoadjuvant
treatment in gastro-esophageal cancer: A meta-analysis of 17
published studies. Eur J Surg Oncol. 43:1607–1616. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takagane A, Terashima M, Abe K, Araya M,
Irinoda T, Yonezawa H, Nakaya T, Inaba T, Oyama K, Fujiwara H and
Saito K: Evaluation of the ratio of lymph node metastasis as a
prognostic factor in patients with gastric cancer. Gastric Cancer.
2:122–128. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kodera Y, Yamamura Y, Shimizu Y, Torii A,
Hirai T, Yasui K, Morimoto T, Kato T and Kito T: Metastatic gastric
lymph node rate is a significant prognostic factor for resectable
stage IV stomach cancer. J Am Coll Surg. 185:65–69. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Komatsu S, Ichikawa D, Miyamae M, Kosuga
T, Okamoto K, Arita T, Konishi H, Morimura R, Murayama Y, Shiozaki
A, et al: Positive lymph node ratio as an indicator of prognosis
and local tumor clearance in N3 gastric cancer. J Gastrointest
Surg. 20:1565–1571. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stotz M, Gerger A, Eisner F, Szkandera J,
Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner
C, et al: Increased neutrophil-lymphocyte ratio is a poor
prognostic factor in patients with primary operable and inoperable
pancreatic cancer. Br J Cancer. 109:416–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Teramukai S, Kitano T, Kishida Y, Kawahara
M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, et al:
Pretreatment neutrophil count as an independent prognostic factor
in advanced non-small-cell lung cancer: An analysis of Japan
multinational trial organisation LC00-03. Eur J Cancer.
45:1950–1958. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li MX, Liu XM, Zhang XF, Zhang JF, Wang
WL, Zhu Y, Dong J, Cheng JW, Liu ZW, Ma L and Lv Y: Prognostic role
of neutrophil-to-lymphocyte ratio in colorectal cancer: A
systematic review and meta-analysis. Int J Cancer. 134:2403–2413.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim
KH and Kim HJ: Prognostic significance of neutrophil lymphocyte
ratio and platelet lymphocyte ratio in advanced gastric cancer
patients treated with FOLFOX chemotherapy. BMC Cancer. 13:3502013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheng CB, Zhang QX, Zhuang LP and Sun JW:
Prognostic value of lymphocyte-to-C-reactive protein ratio in
patients with gastric cancer after surgery: A multicentre study.
Jpn J Clin Oncol. 50:1141–1149. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang J, Guo X, Wang M, Ma X, Ye X and Lin
P: Pre-treatment inflammatory indexes as predictors of survival and
cetuximab efficacy in metastatic colorectal cancer patients with
wild-type RAS. Sci Rep. 7:171662017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Y, Jia H, Yu W, Xu Y, Li X, Li Q and
Cai S: Nomograms for predicting prognostic value of inflammatory
biomarkers in colorectal cancer patients after radical resection.
Int J Cancer. 139:220–231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Proctor MJ, Morrison DS, Talwar D, Balmer
SM, Fletcher CD, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC:
A comparison of inflammation-based prognostic scores in patients
with cancer. A Glasgow inflammation outcome study. Eur J Cancer.
47:2633–2641. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Okugawa Y, Toiyama Y, Yamamoto A,
Shigemori T, Ichikawa T, Yin C, Suzuki A, Fujikawa H, Yasuda H,
Hiro J, et al: Lymphocyte-to-C-reactive protein ratio and score are
clinically feasible nutrition-inflammation markers of outcome in
patients with gastric cancer. Clin Nutr. 39:1209–1217. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hirahara N, Tajima Y, Fujii Y, Kaji S,
Yamamoto T, Hyakudomi R, Taniura T and Kawabata Y: Prognostic
nutritional index as a predictor of survival in resectable gastric
cancer patients with normal preoperative serum carcinoembryonic
antigen levels: A propensity score matching analysis. BMC Cancer.
18:2852018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Migita K, Takayama T, Saeki K, Matsumoto
S, Wakatsuki K, Enomoto K, Tanaka T, Ito M, Kurumatani N and
Nakajima Y: The prognostic nutritional index predicts long-term
outcomes of gastric cancer patients independent of tumor stage. Ann
Surg Oncol. 20:2647–2654. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xishan Z, Ye Z, Feiyan M, Liang X and
Shikai W: The role of prognostic nutritional index for clinical
outcomes of gastric cancer after total gastrectomy. Sci Rep.
10:173732020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC,
Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, et al: Clinical
significance of four molecular subtypes of gastric cancer
identified by the cancer genome atlas project. Clin Cancer Res.
23:4441–4449. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li L and Wang X: Identification of gastric
cancer subtypes based on pathway clustering. NPJ Precis Oncol.
5:462021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rodriquenz MG, Roviello G, D'Angelo A,
Lavacchi D, Roviello F and Polom K: MSI and EBV positive gastric
cancer's subgroups and their link with novel immunotherapy. J Clin
Med. 9:14272020. View Article : Google Scholar : PubMed/NCBI
|
